These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 10492360)
21. Correlation between 18F-fluorodeoxyglucose positron emission tomography and pathologic differentiation in pancreatic cancer. Ahn SJ; Park MS; Lee JD; Kang WJ Ann Nucl Med; 2014 Jun; 28(5):430-5. PubMed ID: 24623151 [TBL] [Abstract][Full Text] [Related]
22. Utility of 18 fludeoxyglucose in preoperative positon-emission tomography-computed tomography (PET-CT) in the early diagnosis of exocrine pancreatic cancer: A study of 139 resected cases. Sánchez-Bueno F; García-Pérez R; Claver Valderas MA; de la Peña Moral J; Frutos Esteban L; Ortiz Ruiz E; Fuster Quiñonero M; Parrilla Paricio P Cir Esp; 2016 Nov; 94(9):511-517. PubMed ID: 27712835 [TBL] [Abstract][Full Text] [Related]
27. Diagnosis of pancreatic cancer using ¹⁸F-FDG PET/CT and CA19-9 with SUVmax association to clinical characteristics. Sun Y; Duan Q; Wang S; Zeng Y; Wu R J BUON; 2015; 20(2):452-9. PubMed ID: 26011335 [TBL] [Abstract][Full Text] [Related]
28. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750 [TBL] [Abstract][Full Text] [Related]
29. Imaging a pancreatic carcinoma xenograft model with 11C-acetate: a comparison study with 18F-FDG. Zhao C; Chen Z; Ye X; Zhang Y; Zhan H; Aburano T; Tian M; Zhang H Nucl Med Commun; 2009 Dec; 30(12):971-7. PubMed ID: 19696689 [TBL] [Abstract][Full Text] [Related]
30. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?]. Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530 [TBL] [Abstract][Full Text] [Related]
31. Contribution of 18F-fluorodeoxyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma. Seo S; Doi R; Machimoto T; Kami K; Masui T; Hatano E; Ogawa K; Higashi T; Uemoto S J Hepatobiliary Pancreat Surg; 2008; 15(6):634-9. PubMed ID: 18987935 [TBL] [Abstract][Full Text] [Related]
32. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer. Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649 [TBL] [Abstract][Full Text] [Related]
33. Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT. Sperti C; Pasquali C; Bissoli S; Chierichetti F; Liessi G; Pedrazzoli S J Gastrointest Surg; 2010 Jan; 14(1):131-40. PubMed ID: 19777315 [TBL] [Abstract][Full Text] [Related]
34. The value of liver-based standardized uptake value and other quantitative 18F-FDG PET-CT parameters in neoadjuvant therapy response in patients with locally advanced rectal cancer: correlation with histopathology. Koç M; Kaya GÇ; Demir Y; Sürücü E; Sarioğlu S; Obuz F; Öztop İ; Görken İB; Sökmen S Nucl Med Commun; 2015 Sep; 36(9):898-907. PubMed ID: 25969176 [TBL] [Abstract][Full Text] [Related]
35. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer. Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838 [TBL] [Abstract][Full Text] [Related]
36. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088 [TBL] [Abstract][Full Text] [Related]
37. Usefulness of dual-phase 18F-FDG PET/CT for diagnosing small pancreatic tumors. Kawada N; Uehara H; Hosoki T; Takami M; Shiroeda H; Arisawa T; Tomita Y Pancreas; 2015 May; 44(4):655-9. PubMed ID: 25815646 [TBL] [Abstract][Full Text] [Related]
38. Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT. Epelbaum R; Frenkel A; Haddad R; Sikorski N; Strauss LG; Israel O; Dimitrakopoulou-Strauss A J Nucl Med; 2013 Jan; 54(1):12-8. PubMed ID: 23166388 [TBL] [Abstract][Full Text] [Related]
39. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT. Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387 [TBL] [Abstract][Full Text] [Related]
40. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. Sendler A; Avril N; Helmberger H; Stollfuss J; Weber W; Bengel F; Schwaiger M; Roder JD; Siewert JR World J Surg; 2000 Sep; 24(9):1121-9. PubMed ID: 11036292 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]